Postmenopausal Vaginal Atrophy Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis by therapy type (Estrogen based drugs, Non-estrogen based drugs, others); Product types (Vaginal gels, Creams, Tablets, Rings, Patches, Others.); End User (Hospitals, Specialty clinics, Others.)
Report Code: TIPRE00013446
| No. of Pages: 150
| Category: Healthcare IT
| Status: Upcoming
Postmenopausal vaginal atrophy (PVA), also referred to as postmenopausal atrophic vaginitis, caused by the vaginal walls' drying, thinning, and inflammation due to reduced estrogen levels. Women with this disorder are more vulnerable to problems of urinary system and chronic infection of vaginal linings. A variety of medications and therapies available in market that focuses on the underlying cause as well as the symptoms of the condition. These therapies also helps women to improve their quality of life. The major trends observed in this market is the shift from systemic estrogen therapies, such as vaginal gels, creams, and patches, to non-estrogenic therapies. Even so the demand for the former therapeutics appears to be high and between the topical and systemic class of estrogen products systemic class dominates the market.
The "Postmenopausal vaginal atrophy therapeutics market to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of postmenopausal vaginal atrophy therapeutics market with detailed market segmentation by of therapy type, product type, end user. The postmenopausal vaginal atrophy therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Postmenopausal vaginal atrophy therapeutics market and offers key trends and opportunities in the market.
n the basis of therapy type, the market is segmented into Estrogen based drugs, Non-estrogen based drugs, others.
n the basis of product types, the market is segmented into Vaginal gels, Creams, Tablets, Rings, Patches, Others.
n the basis of end user, the market is segmented into Hospitals, Specialty clinics, Others.
MARKET DYNAMICS Drivers:
Rise in prevalence of postmenopausal vaginal atrophy.
Growing awareness about the therapies.
Low diagnosis rate
Risk associated with the existing treatment options restricts the market.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the postmenopausal vaginal atrophy therapeutics market based on various segments. It also provides market size and forecast estimates from year 2021 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The postmenopausal vaginal atrophy therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting postmenopausal vaginal atrophy therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting postmenopausal vaginal atrophy therapeutics market in these regions.
IMPACT OF COVID-19 ON POSTMENOPAUSAL VAGINAL ATROPHY THERAPEUTICS MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. The global impacts of the COVID-19 are already starting to be felt, and will significantly affect the postmenopausal vaginal atrophy therapeutics market in 2020.Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
Get more information on this report :
The report covers key developments in the Postmenopausal vaginal atrophy therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Postmenopausal vaginal atrophy therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for postmenopausal vaginal atrophy therapeutics market in the global market. Below mentioned is the list of few companies engaged in the postmenopausal vaginal atrophy therapeutics market.
The report also includes the profiles of key players in Postmenopausal vaginal atrophy therapeutics market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.
Shionogi and Co
QuatRx Pharmaceutical Company
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Get more information on this report :
The List of Companies
2. Accord Healthcare
4. Novo Nordisk
5. Teva Pharmaceuticals
6. Shionogi and Co
7. Bionovo, Inc.
8. QuatRx Pharmaceutical Company
9. Bayer AG
11. Actavis plc